Medication Management of Parkinson's Disease: Early versus Advanced Stages

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 4, 2012, Pages 209-214

  Tsai, Shin Chia ^a   Yuan, Rey Yue ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Motor complications; Neuroprotection; Parkinsonian depression; Switch of dopamine agonists

Indexed keywords

AMANTADINE; AMANTADINE SULFATE; APOMORPHINE; BENSERAZIDE; BENSERAZIDE PLUS LEVODOPA; BIPERIDEN; BROMOCRIPTINE; BROMOCRIPTINE MESILATE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PLACEBO; PRAMIPEXOLE; RASAGILINE; ROPINIROLE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TOLCAPONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIHEXYPHENIDYL;

BINDING AFFINITY; BRADYKINESIA; BRAIN DEPTH STIMULATION; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONFUSION; CONSTIPATION; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG PENETRATION; DRUG PREFERENCE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; ENDOGENOUS DEPRESSION; EVIDENCE BASED MEDICINE; HALLUCINATION; HEART VALVE REGURGITATION; HIGH RISK POPULATION; HUMAN; MAJOR DEPRESSION; MEDICATION THERAPY MANAGEMENT; MEMORY DISORDER; MORNING DOSAGE; MOTOR CONTROL; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SOMNOLENCE; THERAPY DELAY; TREATMENT DURATION; TREMOR; VALVULAR HEART DISEASE;

EID: 84865735047     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.06.010     Document Type: Review

References (66)

1. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 1973, 20:415-455.
2. Chiueh C.C. Dopamine in the extrapyramidal motor function. A study based upon the MPTP-induced primate model of parkinsonism. Ann N Y Acad Sci 1988, 515:226-238.
3. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology 1967, 17:427-442.
4. Chen R.C., Chang S.F., Su C.L., Chen T.H.H., Yen M.F., Wu H.M., Chen Z.Y., et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan County, Taiwan. Neurology 2001, 57:1679-1686.
5. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., Marshall F.J., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386.
6. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957, 180:1200.
7. Carlsson A. A half-century of neurotransmitter research: impact on neurology and psychiatry. Biosci Rep 2001, 21:691-710. Nobel lecture.
8. Miyasaki J.M., Martin W., Suchowersky O., Weiner W.J., Lang A.E. Practice parameter: Initiation of treatment for Parkinson's disease: an evidence-based review: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2002, 58:11-17.
9. Goetz C.G., Poewe W., Rascol O., Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 2005, 20:523-539.
10. Sethi K. Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 2008, 23:S521-S533.
11. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16:448-458.
12. Yuan R.Y., Sheu J.J., Yu J.M., Hu C.J., Tseng I.J., Ho C.S., Yeh C.Y., et al. Methylenetetrahydrofolate reductase polymorphisms and plasma homocysteine in levodopa-treated and non-treated Parkinson's disease patients. J Neurol Sci 2009, 287:64-68.
13. Sibley D.R., Monsma F.J. Molecular biology of dopamine receptors. Trends Pharmacol Sci 1992, 13:61-69.
14. Kvernmo T., Hartter S., Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006, 28:1065-1078.
15. Deleu D., Northway M.G., Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002, 41:261-309.
16. Thobois S., Delamarre-Damier F., Derkinderen P. Treatment of motor dysfunction in Parkinson's disease: an overview. Clin Neurol Neurosurg 2005, 107:269-281.
17. Grosset K.A., Grosset D.G. Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's disease. Clin Ther 2006, 28:1063-1064.
18. Stewart D., Morgan E., Burn D., Grosset D., Chaudhuri K.R., MacMahon D., Needleman F., et al. Dopamine agonist switching in Parkinson's disease. Hosp Med 2004, 65:215-219.
19. Hwang W.J. Medical treatment of Parkinson's disease. Acta Neurologica Taiwanica 2002, 12:44-57.
20. Deuschl G., Schade-Brittinger C., Krack P., Volkmann J., Schafer H., Botzel K., Daniels C., et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 2006, 355:896-908.
21. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000, 342:1484-1491.
22. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., McDermott M., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004, 61:1044-1053.
23. Hauser R.A., Rascol O., Korczyn A.D., Stoessl A.J., Watts R.L., Poewe W., De Deyn P.P., et al. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 2007, 22:2409-2417.
24. Marek K., Seibyl J., Shoulson I., Holloway R., Kieburtz K., McDermott M., Kamp C., et al. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002, 287:1653-1661.
25. Whone A.L., Watts R.L., Stoessl A.J., Davis M., Reske S., Nahmias C., Lang A.E., et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003, 54:93-101.
26. Schapira A.H.V. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007, 64:1083-1088.
27. Olanow C.W., Watts R.L., Koller W.C. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001, 56:S1-88.
28. Goetz C.G., Tanner C.M., Glantz R.H., Klawans H.L. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide. Neurology 1985, 35:749-751.
29. Goetz C.G., Shannon K.M., Tanner C.M., Carroll V.S., Klawans H.L. Agonist substitution in advanced Parkinson's disease. Neurology 1989, 39:1121-1122.
30. U.S. Food and Drug Administration MedWatch 2007. [accessed 14.02.12]. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152695.htm/.
31. Zanettini R., Antonini A., Gatto G., Gentile R., Tesei S., Pezzoli G. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 2007, 356:39-46.
32. Yamamoto M., Uesugi T. Dopamine agonists and valvular heart disease in patients with Parkinson's disease: evidence and mystery. J Neurol 2007, 254:74-78.
33. Goetz C.G., Blasucci L., Stebbins G.T. Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow?. Neurology 1999, 52:1227-1229.
34. Hauser R., Beider C., Stacey M., Hubble J., Seeberger L., Gauger K. Acute versus gradual pramipexole to ropinirole switch. Mov Disord 2000, 15:133.
35. Takahashi H., Nogawa S., Tachibana H., Kawamura J., Abe T., Ogino Y., Kashihara K., et al. Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching. J Int Med Res 2008, 36:106-114.
36. Ohno H., Nakajima M., Fujioka S., Iwamoto K., Kawamura M. Overnight switching from ergot-derived dopamine agonists to pramipexole in patients with Parkinson's disease: An open preliminary trial in Japan. J Clin Neurosci 2009, 16:790-792.
37. Linazasoro G. Conversion from dopamine agonists to pramipexole: an open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004, 251:335-339.
38. Reichmann H., Odin P., Brecht H.M., Koster J., Kraus P.H. Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole. J Neural Transm Suppl 2006, 71:17-25.
39. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2012. [accessed 14.02.12]. http://www.whocc.no/atc_ddd_index/?query=N04BC/.
40. Reichmann H., Herting B., Miller A., Sommer U. Switching and combining dopamine agonists. J Neural Transm 2003, 110:1393-1400.
41. Simuni T., Lyons K.E., Pahwa R., Hauser R.A., Comella C., Elmer L., Weintraub D. Treatment of early Parkinson's disease. Part 1. Eur Neurol 2009, 61:193-205.
42. Hobson D.E., Lang A.E., Wayne Martin W.R., Razmy A., Rivest J., Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002, 287:455-463.
43. LeWitt P.A., Boroojerdi B., MacMahon D., Patton J., Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007, 30:256-265.
44. Horstink M., Tolosa E., Bonuccelli U., Deuschl G., Friedman A., Kanovsky P., Larsen J.P., et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 2006, 13:1170-1185.
45. Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson's disease: a review of the literature. Clin Ther 2006, 28:1-12.
46. Tsai SC, Chiueh CC, Yuan RY. A small-scale phase IV clinical trial of two non-ergot dopamine agonists: slowly switching from ropinirole to pramipexole in patients with Parkinson's disease. Dissertation of Master of Science in Clinical Pharmacy School of Pharmacy, Taipei Medical University, Taiwan, 2009.
47. Onofrj M., Bonanni L., De Angelis M.V., Anzellotti F., Ciccocioppo F., Thomas A. Long half-life and prolonged-release dopamine receptor agonists: a review of ropinirole prolonged-release studies. Parkinsonism Relat Disord 2009, 15(Suppl. 4):S85-S92.
48. Fernandez H.H., Chen J.J. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease. Pharmacotherapy 2007, 27:174S-185S.
49. Andoh T., Chock P.B., Murphy D.L., Chiueh C.C. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol Pharmacol 2005, 68:1408-1414.
50. Hurley D. FDA Committee: rasagiline rejected as disease modifying for Parkinson disease. Neurology Today 2011, 11. 1,6,7.
51. Schrag A. Entacapone in the treatment of Parkinson's disease. Lancet Neurol 2005, 4:366-370.
52. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., Hallett M., et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
53. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., Olanow C.W., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004, 351:2498-2508.
54. Antonini A., Tolosa E., Mizuno Y., Yamamoto M., Poewe W.H. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009, 8:929-937.
55. Walter B.L., Vitek J.L. Surgical treatment for Parkinson's disease. Lancet Neurol 2004, 3:719-728.
56. Brown R.G., MacCarthy B., Gotham A.M., Der G.J., Marsden C.D. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988, 18:49-55.
57. Poewe W. Depression in Parkinson's disease. J Neurol 2007, 254(Suppl. 5):49-55.
58. Maj J., Rogoz Z., Skuza G., Kolodziejczyk K. Antidepressant effects of pramipexole, a novel dopamine receptor agonist. J Neural Transm 1997, 104:525-533.
59. Corrigan M.H., Denahan A.Q., Wright C.E., Ragual R.J., Evans D.L. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000, 11:58-65.
60. Barone P., Scarzella L., Marconi R., Antonini A., Morgante L., Bracco F., Zappia M., et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol 2006, 253:601-607.
61. Bxarone P., Poewe W., Albrecht S., Debieuvre C., Massey D., Rascol O., Tolosa E., et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010, 9:573-580.
62. Bodkin J.A., Amsterdam J.D. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients. Am J Psychiatry 2002, 159:1869-1875.
63. Suchowersky O., Gronseth G., Perlmutter J., Reich S., Zesiewicz T., Weiner W.J. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:976-982.
64. Chiueh C.C., Miyake H., Peng M.T. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv Neurol 1993, 60:251-258.
65. Chiueh C.C., Andoh T., Lai A.R., Lai E., Krishna G. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2000, 2:293-310.
66. Wu R.M., Chen R.C., Chiueh C.C. Effect of MAO-B inhibitors on MPP+ toxicity in vivo. Ann N Y Acad Sci 2000, 899:255-261.